137. Focal cortical dysplasia
8 clinical trials,   4 drugs   (DrugBank: 2 drugs),   1 drug target gene,   50 drug target pathways

Searched query = "Focal cortical dysplasia", "FCD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03198949
(ClinicalTrials.gov)
May 24, 201813/6/2017A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)Epilepsy and Focal Cortical Dysplasia IIDrug: Afinitor (everolimus)Yonsei UniversityNULLRecruiting4 Years40 YearsAll26Phase 2Korea, Republic of
2NCT02451696
(ClinicalTrials.gov)
January 20148/10/2014A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDA Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDEpilepsy;Tuberous Sclerosis Complex;Focal Cortical DysplasiaDrug: EverolimusNYU Langone HealthNULLCompleted2 Years40 YearsAll15Phase 2United States